Gyrolab Spin Blog

Apr 25, 2016 3:09:07 PM

Finding the best platform for fit-for-purpose ADA assays

Gyrolab system delivers

ADA.pngDetermining the immunogenic potential of a therapeutic antibody is a regulatory requirement during clinical development since anti-drug antibodies (ADA) can cause undesirable effects, ranging from loss of drug exposure and efficacy to serious adverse events. Justine Brose and her colleagues at Novimmune SA, Geneva, Switzerland evaluated four platforms to determine which platform and sample pre-treatment procedures could deliver a fit-for-purpose assay for ADA analysis to determine the immunogenicity of the therapeutic antibody Novimab. Of the platforms tested (ELISA and Gyrolab, Meso Scale Discovery, and AlphaLISA platforms) only Gyrolab and MSD platforms met all of their pre-specified assay requirements.

 

Read More

Topics: ADA, immunogenicity


Jun 29, 2015 5:28:00 PM

Gyrolab at AAPS National Biotechnology Conference 2015

Anti-Drug Antibody analysis dominates the Gyrolab related posters

 

Gyrolab_xPlore

The AAPS National Biotechnology Conference, held June 8–10 in San Francisco, USA, was presented as THE pharmaceutical biotechnology meeting. The conference certainly generated a high concentration of scientists from the pharmaceutical and biotechnology industry, ready to network and find out about the latest developments in science and analysis platforms. Gyros Inc. was there with Gyrolab xP workstation and Gyrolab xPlore and we enjoyed a lot of activity at our booth, supported by five independent posters presented during the meeting. Four of these focused on Anti-Drug Antibodies (ADA):

 

Read More

Topics: ADA


Dec 3, 2014 3:24:00 PM

High-performance immunoassays demand precision reagents

Anti-idiotypic antibodies home in on the true target

keyImmunoassays are only as good as the reagents they build on. Following up on the post ‘Success in the balancing act of ADA analysis‘, we found two new articles that clearly show how fine-tuned antibody reagents can support high performance immunoassays.

 

Read More

Topics: Assay Development, ADA


Sep 15, 2014 3:47:00 PM

Success in the balancing act of ADA analysis

Why NovImmune moved from ELISA to Gyrolab xP workstation

ADA-in-the-balance_Anti-Drug Antibodies (ADA) can decrease drug half-life, reduce drug efficacy and even cause serious adverse reactions. Measuring ADA is therefore a key safety concern, but the immunoassays used to do this are complicated by the presence of drug and target in samples, which may severely reduce assay selectivity. This demands immunogenicity assays that are a balancing act between sufficient sensitivity, drug tolerance, and resistance to target interference.

 

Read More

Topics: Assay Development, ADA